In the coming years, mega increased spending on R&D will dwarf revenues. Happens with all start-up bio-techs. They key to the stock's success will be can ONVO continue to attract cash infusions when needed, and if they can, how much will share value be diluted?
Anyone who thinks ONVO isn't going to need mucho financing help in the future is dreaming of sugar plumbs and the tooth fairy. Doesn't mean the guys steering the ship don't know what they are doing. They gotta do what they gotta do, and dilution is just part of it. No bi-tech has ever reached the marketplace without having gone through several cash calls.
Is ONVO overpriced? Any company with costs exceeding revenue is overpriced. Just gotta hang in there until that reverses itself. Of course, the risk is bthat it never will. And that my friends is why people pray.
I totally understand. I was just being facetious. This is my third startup biotech company. Long haul with great payoffs at the end for the most part. Much better odds than Las Vegas! They have a great management team, patents, backed by reputable firms/partnerships, cash reserves...much better odds than vegas